The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Molecular classification of pulmonary carcinoid and large cell NETs
International Agency for Research on Cancer (IARC-WHO), Lyon, France, discusses the heterogeneity of pulmonary carcinoid and large cell neuroendocrine tumors (NETs), and attempts to group these carcinomas. There are three broad groups, which these lung neuroendocrine neoplasm scan fall under, which are based on molecular analysis. One group is defined by genomic characteristics similar to non-small cell lung cancer and has defining mutations such as KEAP1, KRAS, and STK11, whereas another group has a non-endocrine transcriptomic profile. The third group is characterized as small-cell lung cancer-like, due to inactivation of TP53 and RB1, and has an endocrine-like transcriptomic profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
